clinical trials – Page 2

Fungal Drug Discovery for Chronic Disease: History, New Discoveries and New Approaches

mycolabadmin

This article examines how fungi have provided humanity with some of the most important medicines ever created, including penicillin, drugs that prevent organ rejection, and cholesterol-lowering statins. Many of these fungal compounds work as medicines because they target processes that are similar in both fungi and humans, helping them survive competition with other fungi while coincidentally treating human diseases. New researchers are now using modern genetic tools to discover additional fungal medicines, with several promising candidates currently being tested in clinical trials for cancer, depression, and other chronic diseases.

Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey

mycolabadmin

This survey studied how autistic adults feel about using psychedelics like psilocybin mushrooms for mental health. Nearly 70% of participants had tried psychedelics before and most found them helpful for anxiety and depression. Many participants were interested in trying them or participating in research, though legal and practical barriers stood in the way. The study suggests that psychedelics could be a promising treatment option for autistic people with mental health challenges.

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms

mycolabadmin

This comprehensive review examines how medicinal mushrooms can help treat cancer. Certain mushroom species and their compounds, particularly polysaccharides, can boost the immune system to fight cancer cells, reduce chemotherapy side effects, and overcome drug resistance. Multiple mushrooms are currently in clinical trials showing promise in improving cancer patient outcomes when used alongside conventional treatments.

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression

mycolabadmin

This research study is investigating how psilocybin, a compound from certain mushrooms, affects the brain in people with depression. The study involves 50 participants who will receive either psilocybin or a placebo, with their brain activity monitored using advanced imaging scans. Researchers will examine how psilocybin changes blood flow and network activity in brain regions involved in mood regulation, and whether these changes are linked to improvements in depression symptoms.

The development of psilocybin therapy for treatment-resistant depression: an update

mycolabadmin

Psilocybin, a compound found in certain mushrooms, is being studied as a potential treatment for severe depression that doesn’t respond to standard medications. In clinical trials, patients receiving psilocybin alongside psychological support showed significant improvement in depressive symptoms within days to weeks, with benefits lasting for months. Unlike daily antidepressant pills, psilocybin therapy involves one or more carefully supervised dosing sessions in a hospital setting with therapeutic support before and after. Larger studies are underway to confirm its effectiveness and safety before it could potentially become an approved treatment.

Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies

mycolabadmin

This research review examined whether people with schizophrenia can safely participate in psychedelic-assisted therapy treatments. Researchers analyzed 131 studies and found that psychedelics rarely cause new psychosis in the general population (0.002%), though the risk is slightly higher in people with existing schizophrenia (3.8%). While the immediate risk appears manageable, about 13% of people who develop psychosis from psychedelics go on to develop schizophrenia, suggesting caution is still needed.

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common because of new medical treatments that suppress immune function, and some fungi are developing resistance to standard medications. However, exciting new antifungal drugs are in development that work in different ways and may be easier to use. The article discusses how doctors need better ways to identify patients at risk, design better clinical trials, and train more specialists to handle these increasingly complex fungal infections.

Research Topic: clinical trials